Majority retain COVID-19 antibodies for six months after infection
A study has shown that 88 percent of people infected by COVID-19 were able to produce SARS-CoV-2 antibodies after six months.
List view / Grid view
News
Thapsigargin could be used as antiviral to treat COVID-19, study shows
Researchers have discovered that thapsigargin has novel antiviral properties and is effective against COVID-19 in pre-clinical studies.
![Dr Jayakrishna Ambati looking into a microscope - macular degeneration research [Credit: UVA Health].](https://drug.russellpublishing.co.uk/wp-content/uploads/Macular-degeneration-Jayakrishna-Ambati-720x500.jpg)
![Dr Jayakrishna Ambati looking into a microscope - macular degeneration research [Credit: UVA Health].](https://drug.russellpublishing.co.uk/wp-content/uploads/Macular-degeneration-Jayakrishna-Ambati.jpg)
HIV drugs could be repurposed to prevent the onset of macular degeneration
Analysis reveals people taking nucleoside reverse transcriptase inhibitors are significantly less likely to develop dry macular degeneration, a leading cause of age-related vision loss.
Novel AI tool takes a DeepCE dive into potential drugs for COVID-19
A new phenotype-based compound screening technology, called DeepCE, identified 10 compounds that could be repurposed for COVID-19.
Novel protein could neutralise SARS-CoV-2 infection in kidneys
A new protein can trick SARS-CoV-2 and bind to the Spike protein rather than cell membranes in a kidney organoid.
Stem cell study illuminates cause of dilated cardiomyopathy (DCM)
A study using stem cells has revealed that DCM-causing mutations in LMNA disrupt the organisation of DNA in the nucleus of heart muscle cells.
“Organs-on-a-chip” reveal how digestive tract may influence neurological disease
A team has used their new organs-on-a-chip system to replicate the interactions between the brain, liver and colon.
Targeting the HCF-1 protein causes cancerous cells to self-destruct
Disrupting the interaction between the MYC oncogene and its co-factor, host cell factor (HCF)–1, was sufficient to cause Burkitt’s lymphoma cells to self-destruct in vivo.
N439K variant of SARS-CoV-2 is resistant to some neutralising antibodies, shows study
The N439K mutation improves the interaction between SARS-CoV-2 Spike protein and the viral receptor ACE2 and eludes antibody-mediated immunity, say investigators.
Altering balance of fibroblasts could prevent spread of colorectal cancer
Researchers have found that colorectal cancer-associated fibroblasts can be altered using a gremlin 1-neutralising antibody or by overexpressing meflin.
UK offers genomics expertise to identify new SARS-CoV-2 variants
The UK Government has said genomics expertise will be offered to countries around the world to identify new variants of SARS-CoV-2.
Biomarkers predict Alzheimer’s five years before onset
The discovery of early plasma biomarkers for Alzheimer's disease could transform outcomes by enabling patients to begin treatment early.
New ion trap used to create highly accurate mass spectrometer
Researchers have developed a new mass spectrometer that uses rotation frequencies of ionised molecules to measure mass with high accuracy.
Heparin inhibits SARS-CoV-2 invasion, finds study
Research suggests heparin could be repurposed for COVID-19 because it can bind to the SARS-CoV-2 Spike protein and prevent the virus from infecting cells in vitro.
T cells target broad range of SARS-CoV-2 epitopes, study shows
A study has found that T cells combat SARS-CoV-2 by targeting many sites on the coronavirus, not just the Spike protein.
